A third of young British men want to change their appearance and the 'picture perfect culture' on social media is to blame: Survey
More than 40% of men in Britain want to build muscle and one in 10 wants steroids
By Kimberly RodriguesJul 04, 2022
A survey conducted by health and fitness company, Origym comprises more than 2000 people in the UK confirms that social media negatively affects body image.
The survey claims to have found that unrealistic expectations about how you should look, encouraged by the “picture perfect culture” on social media is affecting the mental health of one in 10 men.
Psychologist Rob Willson from the Body Dysmorphic Foundation is reported to have said, "There's lots of pressure from social media to try to conform to certain stereotypes of an idealised beauty and particularly in men.
"This is a real challenge because we're a bit less used to it than women are, we're more recently exposed to these kinds of pressures and regretfully women have been exposed for a lot longer but also there's very little movement at the moment against pressure on men."
Based on a report that was carried in Sky News, 26-year-old George Mycock, from Staffordshire had developed a condition called muscle dysmorphia as a teenager, which leads people to think that they are less muscular than they really are.
According to George who runs MyoMinds to raise awareness regarding these issues, social media is the “devil” in these situations.
Speaking about the influence of social media on negative body image and the dangerous path it can lead you to, he is quoted as saying, "I think it does play a huge part - it's very easy to get engrossed in an echo chamber, you follow the people who agree with your extreme thoughts and they show you more extreme thoughts and it starts spiralling out of control."
He adds, "I got into the fitness industry, the fitness industry community, and I saw all the guys in that were big, muscular, covered in veins, six packs, that stuff, and I thought that's what I needed to adhere to.
"That pursuit came from there and that's when I took on disordered eating, exercise addiction, training 'x' amount of times, being incredibly restrictive how I ate. Eventually it led to suicidal behaviours, suicidal ideations, it led down this dark path."
It is estimated that there are 3,6 users of social media worldwide and it is now a large part of today’s culture. Speaking about how social media can sabotage your body image, the Insider had reported that consistently scrolling through posts, particularly images that evoke negative feelings or elevate a certain body type, can impact how you perceive yourself.
The report adds that because social media is filled with people who only present themselves in their best light - it becomes difficult to evade the posts and images that might make you see your body in a negative way.
The findings of the survey reveal that more than 40% of men in Britain want to build muscle and one in 10 wants steroids to build and transform their body.
In an earlier report, Dr John Skevofilax, chief of Surgery for Signature Clinic in the UK had warned that men are abusing steroids and this can lead to breast growth. As, a result he is reportedly performing hundreds of breast reduction surgeries on men.
He attributes this craze for steroids to shows like Love Island, which is a British dating game show. He is quoted as saying, "If you turn it on, every guy on there has a six pack, his chest is out to here, pecs and everything are blowing out of their shirts, so guys are seeing this and they want to emulate their heroes just like in the eighties when it was Sylvester Stallone and Arnold Schwarzenegger."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.